Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA extends action date for priority review of Amgen's BLA for romiplostim in ITP

April 11, 2008

Exubera labeling updated in the United States

April 11, 2008

Otelixizumab set to enter phase III for new-onset type 1 diabetes

April 11, 2008

PHX-1149 effective in proof-of-concept study in type 2 diabetes patients

April 11, 2008

Generex's Oral-lyn phase III trial begins in North America

April 9, 2008

Biopure receives comment letter regarding U. K. MAA for Hemopure

April 9, 2008

Recent Biovitrum patents describe novel therapeutic agents for obesity

April 9, 2008

Improved pharmacokinetics of second-generation FBPase inhibitor for the treatment of diabetes

April 8, 2008

Vitreoretinal enrolls patients in phase III Vitreosolve trial for diabetic retinopathy

April 8, 2008

Abbott launches Zemplar capsules in the U.K.

April 8, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...